Every 424B that Aeluma, Inc. (ALMU) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow ALMU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALMU filings page.
Aeluma, Inc. has launched an at-the-market offering under a Sales Agreement dated March 20, 2026, authorizing up to $50,000,000 aggregate offering price of common stock. Sales may occur from time to time through Roth Capital Partners as representative and three agent firms, with commissions up to 3%.
The prospectus supplement bases the illustrative share count on 18,002,949 shares outstanding as of March 17, 2026 and shows up to 3,556,187 shares would be issued if $50,000,000 were sold at the March 19, 2026 closing price of $14.06. Proceeds are intended for working capital and general corporate purposes; timing and amounts will vary with market sales.
Aeluma, Inc. is registering up to 14,011,726 shares of common stock for resale by existing selling stockholders. The shares come from prior private offerings, a merger conversion, pre‑merger holders and convertible notes, plus shares issuable on placement agent warrants.
Aeluma will not receive proceeds from stockholder resales, but may receive cash if the warrants are exercised. Its common stock trades on Nasdaq under the symbol ALMU. The company qualifies as an emerging growth and smaller reporting company, using scaled disclosure requirements.
Aeluma, Inc. has filed a resale prospectus covering up to 11,010,002 shares of its Common Stock, which may be sold from time to time by existing selling stockholders. The company’s shares trade on the Nasdaq Capital Market under the symbol ALMU, and Aeluma will not receive any proceeds from these stockholder sales, other than any cash received if placement agent warrants are exercised.
Aeluma develops high-performance optoelectronic devices and photodetector arrays using compound semiconductor materials on large-diameter silicon wafers for applications including 3D imaging, LiDAR, AR/VR, defense, aerospace and communications. The company has raised capital through recent underwritten offerings and note conversions and has secured U.S. government contracts with the Department of Energy, the U.S. Navy and NASA to advance shortwave infrared and quantum sensing technologies.
The prospectus highlights that Aeluma is an early-stage business, not yet in volume production, and faces risks common to speculative semiconductor ventures, including the need for additional capital, reliance on government and key customers, intense competition, regulatory complexity, and potential volatility in demand, supply chains and the broader chip industry.
Aeluma, Inc. has filed a prospectus supplement registering 2,017,498 shares of common stock and 85,653 shares of common stock underlying placement agent warrants. The supplement attaches the company’s latest quarterly report for the period ended September 30, 2025, giving investors updated financial and business information.
For the quarter, revenue rose to $1.4 million, up from $0.5 million a year earlier, mainly from government contracts, while the net loss widened to $1.5 million as the company increased spending on materials, staff, and stock-based compensation to support growth. Aeluma closed two public equity offerings in March and September 2025, boosting cash, cash equivalents, and a certificate of deposit to $38.1 million and alleviating previously disclosed substantial doubt about its ability to continue as a going concern. The company reports that its disclosure controls were not yet effective and is adding finance leadership and staff to improve internal controls.
Aeluma, Inc. filed a Prospectus Supplement updating its prospectus for 11,010,002 shares of common stock. The supplement incorporates the company’s latest Form 10-Q for the quarter ended September 30, 2025 and must be read together with the base prospectus dated October 6, 2023.
In the quarter, revenue reached $1.385 million, up from $481 thousand a year ago, while net loss was $1.493 million. Operating expenses rose to $2.993 million as the company expanded headcount and materials to support programs. Cash, cash equivalents and a certificate of deposit totaled $38.147 million, strengthened by net proceeds of $23.4 million from the September 2025 offering and $12.6 million from the March 2025 offering.
Shares outstanding were 17,857,863 as of November 10, 2025. Management reported disclosure controls and procedures were not effective as of quarter-end and outlined remediation steps, including hiring a CFO and adding accounting resources.